Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Common Equity (2016 - 2025)

Historic Common Equity for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $3.1 billion.

  • Surgery Partners' Common Equity rose 96.73% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year increase of 96.73%. This contributed to the annual value of $3.2 billion for FY2024, which is 533.53% up from last year.
  • According to the latest figures from Q3 2025, Surgery Partners' Common Equity is $3.1 billion, which was up 96.73% from $3.2 billion recorded in Q2 2025.
  • Over the past 5 years, Surgery Partners' Common Equity peaked at $3.2 billion during Q4 2024, and registered a low of $1.1 billion during Q1 2021.
  • Its 5-year average for Common Equity is $2.6 billion, with a median of $3.0 billion in 2023.
  • As far as peak fluctuations go, Surgery Partners' Common Equity skyrocketed by 12328.53% in 2021, and later tumbled by 62.34% in 2025.
  • Over the past 5 years, Surgery Partners' Common Equity (Quarter) stood at $2.0 billion in 2021, then soared by 49.31% to $2.9 billion in 2022, then increased by 3.18% to $3.0 billion in 2023, then increased by 5.34% to $3.2 billion in 2024, then dropped by 1.7% to $3.1 billion in 2025.
  • Its Common Equity stands at $3.1 billion for Q3 2025, versus $3.2 billion for Q2 2025 and $3.2 billion for Q1 2025.